Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Qian

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Journal of Pharmacology and Experimental Therapeutics|November 6, 2009
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonistChuang Lu, Suresh K Balani, Mark G Qian, et al.
Analytical Biochemistry|December 24, 2018
An LC/MS based method to quantify DNA adduct in tumor and organ tissuesChao Li, Linlin Dong, Afrand Kamali, et al.
British Journal of Clinical Pharmacology|April 29, 2016
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentNeeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Molecules (Basel, Switzerland)|April 28, 2023
Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T CellsDong Wei, Kristin L Horton, John Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 6, 2005
Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometrySuresh K Balani, Nelamangala V Nagaraja, Mark G Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2012
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic targetAmi V Patel, David Eaves, Walter J Jessen, et al.
Molecular Cancer Therapeutics|May 22, 2012
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphomaJudy Quiju Shi, Kerri Lasky, Vaishali Shinde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX ModelsMari Kogiso, Lin Qi, Frank K Braun, et al.
Molecular Cancer Therapeutics|August 14, 2020
Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived XenograftsAdnan O Abu-Yousif, Donna Cvet, Melissa Gallery, et al.
Journal of Medicinal Chemistry|November 11, 2011
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905)Matthew O Duffey, Tricia J Vos, Ruth Adams, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Journal of Pharmacology and Experimental Therapeutics|November 6, 2009
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonistChuang Lu, Suresh K Balani, Mark G Qian, et al.
Analytical Biochemistry|December 24, 2018
An LC/MS based method to quantify DNA adduct in tumor and organ tissuesChao Li, Linlin Dong, Afrand Kamali, et al.
British Journal of Clinical Pharmacology|April 29, 2016
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentNeeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Molecules (Basel, Switzerland)|April 28, 2023
Development of a Highly Sensitive Hybrid LC/MS Assay for the Quantitative Measurement of CTLA-4 in Human T CellsDong Wei, Kristin L Horton, John Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 6, 2005
Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometrySuresh K Balani, Nelamangala V Nagaraja, Mark G Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2012
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic targetAmi V Patel, David Eaves, Walter J Jessen, et al.
Molecular Cancer Therapeutics|May 22, 2012
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphomaJudy Quiju Shi, Kerri Lasky, Vaishali Shinde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX ModelsMari Kogiso, Lin Qi, Frank K Braun, et al.
Molecular Cancer Therapeutics|August 14, 2020
Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived XenograftsAdnan O Abu-Yousif, Donna Cvet, Melissa Gallery, et al.
Journal of Medicinal Chemistry|November 11, 2011
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905)Matthew O Duffey, Tricia J Vos, Ruth Adams, et al.
Pageof 3